These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3551350)

  • 21. Rapid estimation of total body clearance of theophylline in patients receiving intravenous aminophylline infusion.
    Lau AH; O'Connor T; Lam G; Lui CY; Al-Bazzaz FJ; Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):12-5. PubMed ID: 3957483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term therapy with sustained-release theophylline.
    Myhre KI; Arnulf V; Walstad RA
    Pharmatherapeutica; 1985; 4(2):92-7. PubMed ID: 3903782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum theophylline and ventilatory function in chronic obstructive lung disease. Comparison between two slow-release formulations of theophylline.
    Tantucci C; Grassi V; Verdecchia P; Cornelli U; Sorbini CA
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):560-4. PubMed ID: 3905630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Results of a serum concentration-oriented dosage of a theophylline depot preparation in ambulatory patients with chronic obstructive lung disease].
    Harder S; Staib AH; Stauder J
    Prax Klin Pneumol; 1985 Jun; 39(6):193-6. PubMed ID: 4022931
    [No Abstract]   [Full Text] [Related]  

  • 25. Oral doxophylline in patients with chronic obstructive pulmonary disease.
    Villani F; De Maria P; Ronchi E; Galimberti M
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):107-11. PubMed ID: 9088999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Slow release theophylline in patients with airways obstruction with particular reference to the effects of food upon serum levels.
    Thompson PJ; Kemp MW; McAllister WA; Turner-Warwick M
    Br J Dis Chest; 1983 Jul; 77(3):293-8. PubMed ID: 6351891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
    Ranke C; Schmidt G; Oellerich M; Sybrecht GW
    Prax Klin Pneumol; 1983 Mar; 37(3):99-108. PubMed ID: 6856564
    [No Abstract]   [Full Text] [Related]  

  • 28. [Comparison of 2 theophylline delayed-action preparations of different galenic forms].
    Hirsch H
    Wien Med Wochenschr; 1983 Aug; 133(15-16):403-8. PubMed ID: 6636797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacokinetic and therapeutic monitoring in the development of theophylline-retard preparations].
    Iwainsky H; Wilke A; Weide W; Schäfer K
    Pharmazie; 1987 Apr; 42(4):242-4. PubMed ID: 3615555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Application of theophylline as an inhalant (author's transl)].
    Kandt D; Sehrt I; Iwainsky H
    Z Erkr Atmungsorgane; 1981 May; 157(2):152-9. PubMed ID: 7314689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum theophylline steady-state levels: comparative study of 2 retard preparations].
    Kaukel E; Koppermann G
    Prax Klin Pneumol; 1983 Mar; 37(3):109-12. PubMed ID: 6856560
    [No Abstract]   [Full Text] [Related]  

  • 32. [Double-blind crossover study on the long-term effects of aminophylline retard tablets on the use of salbutamol aerosol spray].
    Brändli O; Langloh P
    Schweiz Rundsch Med Prax; 1982 Oct; 71(40):1553-8. PubMed ID: 6757909
    [No Abstract]   [Full Text] [Related]  

  • 33. Phyllocontin in chronic airflow obstruction.
    Dunn A; Hoffman N; Wilson RS
    Br J Clin Pract; 1984 Feb; 38(2):63-5. PubMed ID: 6367798
    [No Abstract]   [Full Text] [Related]  

  • 34. Controversies in pulmonary medicine. Aminophylline should be administered for all acute exacerbations of COPD.
    Ziment I; Niewoehner DE
    Am Rev Respir Dis; 1988 Oct; 138(4):1070. PubMed ID: 3202440
    [No Abstract]   [Full Text] [Related]  

  • 35. [Obstructive airway diseases. Basic therapy with pure theophylline in retard form].
    Pollert I
    Fortschr Med; 1982 Mar; 100(12):547-50. PubMed ID: 7042500
    [No Abstract]   [Full Text] [Related]  

  • 36. Serum theophylline levels with oral sustained release theophylline after transfer from intravenous aminophylline in patients with chronic lung disease.
    Silins RA; Butcher MA; Marlin GE
    Br J Clin Pharmacol; 1984 Oct; 18(4):645-7. PubMed ID: 6487509
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-acting versus a long-acting preparation of theophylline ('Xantivent') in the treatment of reversible bronchospasm.
    Andrasch R; Schmitz-Schumann M
    Pharmatherapeutica; 1984; 3(10):668-77. PubMed ID: 6463066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis.
    Jenkins PF; White JP; Jariwalla AJ; Anderson G; Campbell IA
    Br J Dis Chest; 1982 Jan; 76(1):57-60. PubMed ID: 7037034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combined effect of theophylline and terbutaline in patients with chronic obstructive airway diseases.
    Lamont H; van der Straeten M; Pauwels R; Moerman E; Bogaert M
    Eur J Respir Dis; 1982 Jan; 63(1):13-22. PubMed ID: 7040097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.